Cover Image
市場調查報告書

心肌缺血:開發平台分析

Myocardial Ischemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229788
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
心肌缺血:開發平台分析 Myocardial Ischemia - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 84 Pages
簡介

供給心肌的血流和氧不足就會引起心缺血(心肌缺血)。症狀有身體左側的胸部疼痛(心絞痛),頭或下巴疼痛、肩膀及手腕疼痛、皮膚黏黏的、呼吸困難、噁心及嘔吐等。心肌缺血有可能造成冠狀動脈疾病(動脈粥狀硬化性心血管疾病),凝血,冠狀動脈痙攣與嚴重疾病等症狀。根據研究發現會提升致病風險的因素有香煙,糖尿病,高血壓,血中含高膽固醇或中性脂肪值,運動不足,肥胖,家族病史等。

本報告提供心肌缺血的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞及發表的企業和研究機關開發中的治療藥、治療藥評估、後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

心肌缺血概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

心肌缺血:企業開發中的治療藥

心肌缺血:大學/機關研究中的治療藥

心肌缺血:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

心肌缺血:企業開發中的產品

心肌缺血:大學/機關研究中的產品

心肌缺血的治療藥的開發企業

  • Bayer AG
  • Cellmid Limited
  • CohBar, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Miltenyi Biotec GmbH
  • NoNO, Inc.
  • Shire Plc
  • Symic Biomedical, Inc.
  • Taxus Cardium Pharmaceuticals Group Inc.
  • ViroMed Co., Ltd.

心肌缺血:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

心肌缺血:暫停中的計劃

心肌缺血:開發中止的產品

心肌缺血:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8431IDB

Summary

Global Markets Direct's, 'Myocardial Ischemia - Pipeline Review, H2 2016', provides an overview of the Myocardial Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia
  • The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects
  • The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocardial Ischemia Overview
  • Therapeutics Development
    • Pipeline Products for Myocardial Ischemia - Overview
    • Pipeline Products for Myocardial Ischemia - Comparative Analysis
  • Myocardial Ischemia - Therapeutics under Development by Companies
  • Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes
  • Myocardial Ischemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Myocardial Ischemia - Products under Development by Companies
  • Myocardial Ischemia - Products under Investigation by Universities/Institutes
  • Myocardial Ischemia - Companies Involved in Therapeutics Development
    • Bayer AG
    • Cellmid Limited
    • CohBar, Inc.
    • Lixte Biotechnology Holdings, Inc.
    • Miltenyi Biotec GmbH
    • NoNO, Inc.
    • Shire Plc
    • Symic Biomedical, Inc.
    • Taxus Cardium Pharmaceuticals Group Inc.
    • ViroMed Co., Ltd.
  • Myocardial Ischemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alda-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alferminogene tadenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AntimiR-199a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-606583 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMK-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EP-80317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Humanin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-030 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myocardial Ischemia - Dormant Projects
  • Myocardial Ischemia - Discontinued Products
  • Myocardial Ischemia - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
      • Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
      • Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
      • Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology
      • Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
      • Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
      • May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
      • Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
      • Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy
      • Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study
      • Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition
      • Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease
      • Nov 03, 2010: Cardium Awarded Grant Under QTDP Program
      • Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myocardial Ischemia, H2 2016
  • Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Myocardial Ischemia - Pipeline by Bayer AG, H2 2016
  • Myocardial Ischemia - Pipeline by Cellmid Limited, H2 2016
  • Myocardial Ischemia - Pipeline by CohBar, Inc., H2 2016
  • Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
  • Myocardial Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2016
  • Myocardial Ischemia - Pipeline by NoNO, Inc., H2 2016
  • Myocardial Ischemia - Pipeline by Shire Plc, H2 2016
  • Myocardial Ischemia - Pipeline by Symic Biomedical, Inc., H2 2016
  • Myocardial Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2016
  • Myocardial Ischemia - Pipeline by ViroMed Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Myocardial Ischemia - Dormant Projects, H2 2016
  • Myocardial Ischemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Myocardial Ischemia, H2 2016
  • Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top